Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Inflammatory Breast Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Paclitaxel 6Cyclophosphamide 5pembrolizumab 3Taxes 3Specimen Handling 3Doxorubicin 3Carboplatin 3eribulin 2Trastuzumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2sargramostim 1ruxolitinib 1pertuzumab 1onvansertib 1olaparib 1cobimetinib 1atezolizumab 1X-Rays 1Therapeutics 1Radiotherapy 1Radiation 1Panitumumab 1Palliative Care 1Methods 1Magnetic Resonance Spectroscopy 1Letrozole 1Gonadotropin-Releasing Hormone 1Exercise Test 1Epirubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Inflammatory Breast Neoplasms × onvansertib × Clear all
NCT05383196 2026-02-11

Onvansertib + Paclitaxel In TNBC

Dana-Farber Cancer Institute

Phase 1/2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡